Advertisement

Janssen Submits Application to U.S. FDA to Expand Indication for Daratumumab (DARZALEX®)

Janssen Biotech, Inc. announced today a supplemental Biologics License Application (sBLA) for daratumumab (DARZALEX®) has been submitted to the U.S. Food and Drug Administration (FDA).

 Janssen

click me